基于巴西乙醇提取物的水凝的配方和评估,用于促进糖尿病伤口愈合
Huanglin Huo1, Zhenhua Zhou1, Rongxiang Guo2
1The First Affiliated Hospital of Guangdong Pharmaceutical University, MOE Key Laboratory of Glucolipid Metabolic Disorder, Guangdong Provincial TCM Key Laboratory for Metabolic Diseases, Traditional Chinese Medicine Research Institute (Guangdong Provincial Research Center of Integration of Traditional Chinese Medicine and Western Medicine in Metabolic Diseases), Guangdong Pharmaceutical University, Guangzhou, 510006, China.
BMC biotechnology
|February 21, 2026
概括
一种新的水凝敷料,EEP/PS,通过减少炎症,抗击感染和促进愈合,有效治疗糖尿病伤口. 这种生物材料显示了先进的糖尿病伤口护理的前景.
科学领域:
- 生物材料科学 生物材料科学
- 伤口愈合 治愈 伤口愈合
- 再生医学是一种再生医学.
背景情况:
- 糖尿病性伤口由于炎症,感染风险和不良血管形成 (血管新生) 构成重大临床挑战.
- 现有的治疗方法往往无法有效地解决这些伤口的复杂微环境.
研究的目的:
- 开发和评估用于治疗糖尿病伤口的多功能水凝敷料 (EEP/PS).
- 评估水凝的特性,包括抗氧化,抗炎,抗菌和治疗能力.
主要方法:
- 一种水凝敷料 (EEP/PS) 是使用普鲁兰,巴西乙醇提取物和聚乙烯醇合成的.
- 在体外研究中评估了抗氧化,抗炎 (细胞因子下调) 和抗菌 (对抗大肠杆菌,金黄色杆菌) 作用.
- 在体内研究中使用糖尿病老鼠模型来评估伤口关闭,再上皮化,原沉积,血管生成和炎症.
主要成果:
- EEP/PS表现出多孔结构,良好的机械性能,热稳定性和持续释放性.
- 水凝表现出强大的抗氧化活性,增强了细胞迁移,并抑制了关键的促炎细胞因子 (TNF-α,IL-6,IL-1β).
- 通过促进愈合机制和减少炎症,EP/PS加速了糖尿病伤口的关闭,显示出血静和生物相容性.
结论:
- 多功能EEP/PS水凝敷料显示出治疗糖尿病伤口的巨大潜力.
- 它的综合性质解决了糖尿病伤口愈合的关键挑战,表明了临床应用的强大翻译前景.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...